Psilocybin Science & News

A new study published in Nature Communications (May 2026) found that a single dose of psilocybin — the active compound in magic mushrooms and magic truffles — causes lasting psilocybin brain changes that are still visible one full month after the experience.

This is the first time scientists measured both the brain during a trip and the brain's physical structure four weeks after. The results help explain why so many people say one powerful psilocybin experience can shift how they think and feel for weeks.

Why do magic mushrooms cause hallucinations? A 2026 neuroscience study finally has the answer — and it's as poetic as it is precise. Your brain doesn't invent hallucinations from nothing. It turns off incoming reality and starts replaying memories instead. As the lead researcher put it: "a bit like partial dreaming."

Psilocybin cluster headache treatment sounds radical. But for more than two decades, people with cluster headache — widely regarded as the most painful condition known to medicine — have been quietly using magic mushrooms to stop their attack cycles. They did this long before any clinical trial existed. Now, science is finally catching up. A new Australian study called the PEACE trial is about to test this approach in a funded, rigorous setting for the first time in the Southern Hemisphere.

At Magic Mushrooms Shop, we know many customers who use psilocybin mushrooms for cluster headache relief — and many of them report promising results. We always encourage you to do this together with a doctor or therapist and not to self midicate. In this article we explain what the research shows, what the PEACE trial is testing, and why this matters to millions of people with few other options.

In January 2025, a landmark ruling made magic mushrooms India legal news worldwide. The Kerala High Court decided that psilocybin-containing fungi are not a scheduled narcotic or psychotropic substance under India's strict drug law. As a result, the judgment created a legal grey area affecting 1.4 billion people — and opened the door to future psilocybin research in one of the world's most populous countries.

In this article: Lanmaoa asiatica is a wild mushroom from Yunnan, China, that causes one of the strangest hallucinations ever documented — vivid, lifelike visions of tiny people, just 2 cm tall, marching, dancing, and climbing the furniture around you.

Scientists have been studying it for years. Remarkably, they still have no idea what causes it. Here is what we know.

In this article: On April 18, 2026, President Trump signed a landmark psychedelics executive order directing the FDA, DEA, and VA to fast-track research and access for psychedelic treatments — including psilocybin and ibogaine. We were on holiday last week, so here’s a clear, friendly catch-up on what the order says, why it matters, and what it means for the future of psychedelic medicine.

Since January 1, 2026, the Czech Republic allows Czech Republic psilocybin therapy for patients with treatment-resistant depression. Psychiatrists can now prescribe synthetic psilocybin under strict clinical conditions. This makes Czechia the first EU member state with a full legal framework for medical psilocybin. In this article, you will learn how the law works, who qualifies, and what the latest science says.

In this article: In April 2026, the largest psychedelic brain study ever published appeared in Nature Medicine. Researchers from five countries scanned more than 500 brain sessions. They found that psilocybin, LSD, mescaline, DMT, and ayahuasca all do the same two things to the human brain — despite being completely different molecules.

Here is what they found, why it matters, and what it means for the future of magic mushroom research.

Imagine living with a body that shakes, a mood that sinks and medicines that help your muscles a little but do almost nothing for the sadness and anxiety. Now imagine a single treatment that lifts your mood, sharpens your thinking and improves your movement. That is exactly what researchers at the University of California San Francisco found when they gave psilocybin to Parkinson's patients for the first time.